Viewing nowCombinationDapaenmet Extended-Release Tablet 10/1000 mg (Dapagliflozin, Metformin)
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.

MFDS item code 202300145 · Approved 2023.01.06
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to help adults with type 2 diabetes manage their blood sugar levels through the combination of dapagliflozin and metformin. It is administered as an adjunct to diet and exercise regimen and is effective even when blood sugar is not adequately controlled. Additionally, for patients with cardiovascular disease or risk factors, it is necessary to refer to expert clinical trial information regarding the use of this medication. Overall, this drug assists in blood sugar control and cardiovascular health for patients with type 2 diabetes.
The dosage of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function tends to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication helps manage blood sugar levels. Before taking it, kidney function must be checked. If renal function is poor, the drug may accumulate in the body, posing risks. It should not be used during acute illnesses such as severe infection, dehydration, heart problems, or acute myocardial infarction. It is not to be administered to pregnant or nursing women. This medication contains lactose, so patients with lactose intolerance should avoid taking it. When taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, necessitating caution. During treatment, genital and urinary tract infections may develop, so immediate treatment is required if symptoms arise. Signs of reduced fluid volume or hypotension may occur, particularly if dehydrated. A rare side effect called lactic acidosis may occur; if symptoms like fatigue, muscle pain, shortness of breath, or abdominal pain arise, consult a physician immediately. Vitamin B12 levels may decrease; thus, regular blood tests are advised during long-term use. Alcohol can increase the risk of side effects, so excessive drinking should be avoided during treatment. Before undergoing surgery or imaging tests with contrast agents, the medication should be discontinued for a period, and it may be restarted once normal kidney function is confirmed. Older adults or those with diminished renal function require dose adjustments and monitoring of kidney function. In case of overdose, seek medical treatment immediately. The safety of this medication has not been established for children, so it should not be used in pediatric populations. Dizziness may occur during treatment, necessitating caution when driving or operating machinery. Keep this medication out of the reach of children and store it in its original container to prevent misuse and degradation of quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture; therefore, it must be stored in a tightly sealed container. It is important to maintain storage temperatures between 1 to 30 degrees Celsius to preserve the medication's effectiveness and safety.
Yellow, oval-shaped, bilayer, extended-release film-coated tablets
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donghwa Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.